Cabozantinib for Patients With Recurrent or Progressive Meningioma

Conditions

Cabozantinib — DRUG
Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets. The starting dose for all participants is 60 mg per day by mouth. The study doctor may reduce a participant's dose to 40 mg per day, 20 mg per day, or 20 mg every other day depending on severity of side effects. The study doctor may also increase the dose back up to 60 mg per day if side effects improve.

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

Experimental: Cabozantinib
Participants will self-administer cabozantinib 60 mg at the same time daily by mouth on a continuous 28-day schedule. Participants will continue to take this medication as long as they are deriving benefit from it without significant treatment-related toxicities.

Progression free survival (PFS) [ Time Frame: 6 months ]

Facility	City	State	ZIP	Site coordinators
Miami Cancer Institute at Baptist Health, Inc.	Miami	Florida	33176	Rupesh Kotecha, M.D. [email protected] 786-596-2000 Anais Vega [email protected] (786) 596-2000 Rupesh R Kotecha, MD (PRINCIPAL_INVESTIGATOR)
Memorial Sloan Kettering Cancer Center	New York	New York	100653	Thomas Kaley, M.D. [email protected] 212-639-5122
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Alexander Mohler, M.D. [email protected] 615-936-8422

By research site